Could a cell infusion before kidney transplant reduce rejection?
NCT ID NCT03726307
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This early-phase study tests whether a single infusion of special immune cells (regulatory dendritic cells) from a living kidney donor can safely reduce the risk of organ rejection in the recipient. Fourteen kidney transplant patients will receive the cell infusion one week before surgery and be monitored for two years. The main goal is to check for serious side effects, infections, or rejection episodes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pittsburgh, Starzl Transplantation Institute
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.